Price
$22.12-10.15%Social Signal Score
Analyst Ratings
21 analystsRevenue
$1.37B+90.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey N. Simmons
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 9,650
- Beta
- 1.68
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.28
Financials
Revenue
$1.37B+90.3%Net Income
$54.00MEBITDA
$274.00M+94.5%Free Cash Flow
$244.00M+505.5%EPS (diluted)
$0.11Shares Outstanding (diluted)
505.90M+40.2%Operating Expenses
$541.00MCash & Debt
$530.00MReturn of Capital
$34.00MRevenue by Segment (annual)
$7.08BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.71B | $-232.00M | $-0.47 |
| 2024 | $4.44B | $338.00M | $0.68 |
| 2023 | $4.42B | $-1.23B | $-2.50 |
| 2022 | $4.41B | $-78.00M | $-0.15 |
| 2021 | $4.76B | $-483.00M | $-0.97 |
| 2020 | $3.27B | $-560.10M | $-1.27 |
| 2019 | $3.07B | $67.90M | $0.18 |
| 2018 | $3.07B | $86.50M | $0.28 |
| 2017 | $2.89B | $-310.70M | $-0.87 |
| 2016 | $2.91B | $-47.90M | $-0.13 |
| 2015 | $2.91B | $-210.80M | $-0.59 |
Valuation
ELANhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (17)
- Newsmarketbeat.com·10d ago·Neutral
Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.
View source ↗ - Newsbusinesswire.com·11d ago·Positive
ISG Announces 2026 ISG Women in Digital Awards Winners for EMEA LONDON--(BUSINESS WIRE)-- #EMEA--Leaders with Elanco, DiversITy-talent, NHS 24, Amazon Web Services, IFS Nexus Black and Otermans Institute won ISG Women in Digital Awards for EMEA.
View source ↗ - News (RSS)seekingalpha·13d ago·Positive
Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·25d ago·Neutral
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026.
View source ↗ - News (RSS)fool·31d ago·Positive
Elanco Director Purchases 40,000 Shares for $936,000 Purchasing 40,000 shares is a bullish signal for shareholders.
View source ↗ - Newsfool.com·31d ago·Neutral
Elanco Director Purchases 40,000 Shares for $936,000 The purchase was valued at $936,000. This investment increased the insider's direct equity position by 27%.
View source ↗ - Newsprnewswire.com·41d ago·Neutral
…oclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.
View source ↗ - News (RSS)seekingalpha·47d ago·Neutral
Elanco Animal Health: New Products To Support Growth
View source ↗ - Newsseekingalpha.com·47d ago·Neutral
Elanco Animal Health: New Products To Support Growth I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.
View source ↗ - News (RSS)fool·47d ago·Positive
Director's Confidence Visible as Elanco Leader Buys 10,000 Shares Insider buys into strength as the Elanco stock price has outperformed the S&P 500 over the last 12 months.
View source ↗ - Newsfool.com·48d ago·Positive
Director's Confidence Visible as Elanco Leader Buys 10,000 Shares The director upped their stake by 10,000 shares. This purchase increased the insider's direct equity holdings by 10%.
View source ↗ - News (RSS)yahoo·54d ago·Positive
Elanco (ELAN) Q2 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN's innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program an
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Elanco Animal Health Q2 Earnings Call Highlights Elanco Animal Health NYSE: ELAN reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth.
View source ↗ - 4chan /biz/biz·59d ago·Neutral
CAM ON ELAN MASK
View source ↗
Earnings
Fri, Nov 6(in 4 weeks)
Consensus estimate $0.20 per share
Typical surprise +19.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.34 vs $0.27beat
- Wed, May 6$0.40 vs $0.35beat
- Tue, Feb 24$0.13 vs $0.11beat
- Wed, Nov 5$0.19 vs $0.13beat
- Thu, Aug 7$0.26 vs $0.20beat
- Wed, May 7$0.37 vs $0.31beat
Estimates and results for ELAN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELAN officers and directors.
- Bought
- $1.7m
- Sold
- —
7 trades
0 trades
- Kurzius Lawrence Erikbought
- O'neill Shivbought
- Harrington Michael Jbought
- Vanhimbergen Robert Mbought
- Herendeen Paulbought
- Modi Rajeev A.bought
- Simmons Jeffrey Nbought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (18d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (11d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (38d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (16d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (12d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2024 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (13d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (12d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (13d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (27d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (34d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 7, 2023 (13d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 7, 2023 (11d later)Sell$1,001 - $15,000
- Daniel Scott Sullivansenate · AK · disclosed Jul 26, 2023 (238d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (20d later)Sell$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.